Clinical trials: Primary Headache Disorders
Migraine
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
- Trial name
- NCT05016661
- Testing
- ABP-450
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 466 people
- Sponsor
- AEON Biopharma, Inc.
Episodic Migraine
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have…
- Trial name
- NCT03927144
- Testing
- AMG334, Oral Prophylactic
- Where
- 112 sites in United States, Argentina and 16 more
- Volunteers
- 621 people
- Sponsor
- Amgen
Migraine Headache
Relief of Migraine Pain Through Electro Stimulation
This study will evaluate transcutaneous electro stimulation device developed by Siano for adequacy, safety and efficacy for the treatment and/or prevention of migraine pain for migraine sufferers.
- Trial name
- NCT02453399
- Where
- Israel
- Volunteers
- 87 people
- Sponsor
- Theranica
Migraine
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following…
- Trial name
- NCT04068051
- Testing
- AXS-07
- Where
- 51 sites in United States
- Volunteers
- 706 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine Disorders
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed drug in pediatric subjects with migraines.
- Trial name
- NCT00604812
- Testing
- rizatriptan benzoate (5 mg), rizatriptan benzoate (10 mg)
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Migraine Disorders
Sumatriptan and Naratriptan Pregnancy Registry
Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However, the peak prevalence of migraine is in women of childbearing age.
- Trial name
- NCT01059604
- Testing
- Sumatriptan, Naratriptan, Sumatriptan-naproxen combination
- Volunteers
- 868 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Study to understand the effects of migraine treatments on blood pressure in participants with migraine. The primary hypothesis is that the effect on semi-recumbent mean arterial pressure following the coadministration of…
- Trial name
- NCT00701389
- Testing
- telcagepant potassium, sumatriptan
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC